Peripheral administration of a novel diketopiperazine, NNZ 2591, prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats

Neuropharmacology

Volumn 53, Issue 6, 2007, Pages 749-762

  Guan, J ^a   Mathai, S ^a   Harris, P ^c   Wen, J Y ^b   Zhang, R ^a   Brimble, M ^c   Gluckman, P ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

Author keywords

Central uptake; Diketopiperazine; Hypoxia ischemia; Neuroprotection; Rats

Indexed keywords

ALBUMIN; APOPTOSIS INDUCING FACTOR; CASPASE 3; CYCLOGLYCYL 2 ALLYLPROLINE; CYCLOGLYCYLPROLINE; PIPERAZINEDIONE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN DAMAGE; BRAIN HYPOXIA; BRAIN INJURY; BRAIN ISCHEMIA; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG PROTEIN BINDING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MICROGLIA; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SOMATOSENSORY CORTEX; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ASTROCYTES; BRAIN; BRAIN INJURY, CHRONIC; DIKETOPIPERAZINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; HYPOXIA-ISCHEMIA, BRAIN; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; TIME FACTORS; TREATMENT OUTCOME;

EID: 34948892049     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2007.08.010     Document Type: Article

References (41)

1. Amedjikouh M., and Ahlberg P. Synthesis of chiral diamines using novel 2 trichloromethyloxazolidin-4-one precursors derived from 5-oxo-proline and proline. Tetrahedron 13 (2002) 2229-2234
2. Arredondo G., Martinez-Jorda R., Calvo R., Aguirre C., and Suarez E. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int. J. Clin. Pharmacol. Ther. 32 (1994) 361-364
3. Beilharz E.J., Russo V.C., Butler G., Baker N.L., Connor B., Sirimanne E.S., Dragunow M., Werther G.A., Gluckman P.D., Williams C.E., and Scheepens A. Co-ordinated and cellular specific induction of the components of the IGF/IGFBP axis in the rat brain following hypoxic-ischemic injury. Brain Res. Mol. Brain Res. 59 (1998) 119-134
4. Beilharz E.J., Williams C.E., Dragunow M., Sirimanne E.S., and Gluckman P.D. Mechanisms of delayed cell death following hypoxic-ischemic injury in the immature rat: evidence for apoptosis during selective neuronal loss. Brain Res. Mol. Brain Res. 29 (1995) 1-14
5. Cao Y., Gunn A.J., Bennet L., Wu D., George S., Gluckman P.D., Shao X.M., and Guan J. Insulin-like Growth Factor (IGF)-1 suppresses oligodendrocyte caspase-3 activation and increases glial proliferation after ischemia in near-term fetal sheep. J. Cereb. Blood Flow Metab. 23 (2003) 739-747
6. Degterev A., Huang Z., Boyce M., Li Y., Jagtap P., Mizushima N., Cuny G.D., Mitchison T.J., Moskowitz M.A., and Yuan J. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat. Chem. Biol. 1 (2005) 112-119
7. Dziegielewska K.M., Hinds L.A., Mollgard K., Reynolds M.L., and Saunders N.R. Blood-brain, blood-cerebrospinal fluid and cerebrospinal fluid-brain barriers in a marsupial (Macropus eugenii) during development. J. Physiol. 403 (1988) 367-388
8. Endrenyi L. Drug distribution. In: Kalant H., and Roschlau W.H.E. (Eds). Principles of Medical Pharmacology (1998), Press at Oxford University Press, Oxford 28-37
9. Faden A.I., Knoblach S.M., Cernak I., Fan L., Vink R., Araldi G.L., Fricke S.T., Roth B.L., and Kozikowski A.P. Novel diketopiperazine enhances motor and cognitive recovery after traumatic brain injury in rats and shows neuroprotection in vitro and in vivo. J. Cereb. Blood Flow Metab. 23 (2003) 342-354
10. Faden A.I., Knoblach S.M., Movsesyan V.A., and Cernak I. Novel small peptides with neuroprotective and nootropic properties. J. Alzheimers Dis. 6 (2004) S93-S97
11. Faden A.I., Movsesyan V.A., Knoblach S.M., Ahmed F., and Cernak I. Neuroprotective effects of novel small peptides in vitro and after brain injury. Neuropharmacology 49 (2005) 410-424
12. Fisher M., and Schaebitz W. An overview of acute stroke therapy. Arch. Intern. Med. 160 (2000) 3196-3206
13. Fossan G., Cavanagh M.E., Evans C.A., Malinowska D.H., Mollgard K., Reynolds M.L., and Saunders N.R. CSF-brain permeability in the immature sheep fetus: a CSF-brain barrier. Brain Res. 350 (1985) 113-124
14. Fujimura M., Morita-Fujimura Y., Murakami K., Kawase M., and Chan P.H. Cytosolic redistribution of cytochrome c after transient focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 18 (1998) 1239-1247
15. Gehrmann J., Banati R.B., Wiessner C., Hossmann K.A., and Kreutzberg G.W. Reactive microglia in cerebral ischaemia: an early mediator of tissue damage?. Neuropathol. Appl. Neurobiol. 21 (1995) 277-289
16. Ginsberg M.D., and Busto R. Rodent models of cerebral ischemia. Stroke 20 (1989) 1627-1642
17. Gladsrone D.J., Black S.E., and Hakim A.M. Toward wisdom from failure - lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 33 (2002) 2123-2136
18. Guan J., Beilharz E.J., Skinner S.J., Williams C.E., and Gluckman P.D. Intracerebral transportation and cellular localisation of insulin-like growth factor-1 following central administration to rats with hypoxic-ischemic brain injury. Brain Res. 853 (2000) 163-173
19. Guan J., Gunn A.J., Sirimanne E.S., Tuffin J., Gunning M.I., Clark R., and Gluckman P.D. The window of opportunity for neuronal rescue with insulin-like growth factor-1 after hypoxia-ischemia in rats is critically modulated by cerebral temperature during recovery. J. Cereb. Blood Flow Metab. 20 (2000) 513-519
20. Guan J., Miller O.T., Waugh K.M., McCarthy D., and Gluckman P.D. Insulin-like growth factor-1 improves somatosensory function and reduces the extent of cortical infarction and ongoing neuronal loss after hypoxia-ischemia in rats. Neuroscience 105 (2001) 299-306
21. Guan J., Thomas G.B., Lin H., Mathai S., Bachelor D.C., George S., and Gluckman P. Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology 47 (2004) 892-903
22. Guan J., Williams C., Gunning M., Mallard C., and Gluckman P. The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats. J. Cereb. Blood Flow Metab. 13 (1993) 609-616
23. Han B.H., Xu D., Choi J., Han Y., Xanthoudakis S., Roy S., Tam J., Vaillancourt J., Colucci J., Siman R., Giroux A., Robertson G.S., Zamboni R., Nicholson D.W., and Holtzman D.M. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J. Biol. Chem. 277 (2002) 30128-30136
24. Hoffmann T., Lanig H., Waibel R., and Geneiner P. Rational molecular design and EPC synthesis of a Type VI β-turn inducing peptide mimetic. Angew. Chem. Int. Ed. 40 (2001) 3361-3364
25. Ikegami H., and Prasad C. Neuropeptide-dopamine interactions. V. Cyclo(His-Pro) regulation of striatal dopamine transporter complex. Peptides 11 (1990) 145-148
26. Koenig M.L., Sgarlat C.M., Yourick D.L., Long J.B., and Meyerhoff J.L. In vitro neuroprotection against glutamate-induced toxicity by pGlu-Glu-Pro-NH(2) (EEP). Peptides 22 (2001) 2091-2097
27. Kraig R.P., Lascola C.D., and Cagiano A. Glial response to brain ischemia. In: Kettenmann H., and Ransom B.R. (Eds). Neuroglia (1995), Oxford University Press, New York 964-976
28. Kumari R., Willing L.B., Krady J.K., Vannucci S.J., and Simpson I.A. Impaired wound healing after cerebral hypoxia-ischemia in the diabetic mouse. J. Cereb. Blood Flow Metab. 27 (2007) 710-718
29. Lees K.R. Management of acute stroke. Lancet Neurol. 1 (2002) 41-50
30. Louw D.F., Masada T., and Sutherland G.R. Ischemic neuronal injury is ameliorated by astrocyte activation. Can. J. Neurol. Sci. 25 (1998) 102-107
31. Panickar K.S., and Norenberg M.D. Astrocytes in cerebral ischemic injury: morphological and general considerations. Glia 50 (2005) 287-298
32. Pardridge W.M. Transnasal and intraventricular delivery of drugs. In: Pardridge W.M. (Ed). Peptide Drug Delivery to the Brain (1991), Pressed at Raven Press, New York 99-122
33. Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2 (2005) 3-14
34. Paxinos G., and Watson C.D. The Rat Brain Stereotaxic Coordinations (1982), Pressed at Academic press, New York
35. Pizzi M., Boroni F., Benarese M., Moraitis C., Memo M., and Spano P. Neuroprotective effect of thyrotropin-releasing hormone against excitatory amino acid-induced cell death in hippocampal slices. Eur. J. Pharmacol. 370 (1999) 133-137
36. Samonina G., Ashmarin I., and Lyapina L. Glyproline peptide family: review on bioactivity and possible origins. Pathophysiology 8 (2002) 229-234
37. Seebach D., Boes M., Narf R., and Schweizer W.B. Alkylation of amino acids without loss of the optical activity: preparation of alpha-substituted proline derivatives. A case of self-reproduction of chirality. J. Am. Chem. Soc. 105 (1983) 5390-5398
38. Swanson R.A., Ying W., and Kauppinen T.M. Astrocyte influences on ischemic neuronal death. Curr. Mol. Med. 4 (2004) 193-205
39. Tamura K.A., and Sano K. Delayed neuronal death in the rat hippocampus following transient forebrain ischemia. Acta Neuropathol. 64 (2000) 139-147
40. Yuan J., Lipinski M., and Degterev A. Diversity in the mechanisms of neuronal cell death. Neuron 40 (2003) 401-413
41. Zhang R., Ashton J., Horii A., Darlington C.L., and Smith P.F. Immunocytochemical and stereological analysis of GABA(B) receptor subunit expression in the rat vestibular nucleus following unilateral vestibular deafferentation. Brain Res. 1037 (2005) 107-113